Tag: ASX: ALA
Arovella’s ALA-101 inches toward clinic following key manufacturing achievement
Arovella Therapeutics Ltd, the biotechnology company specialising in iNKT cell therapy, announced that the Good Manufacturing Practice (GMP)-grade lentiviral vector for its lead product, ALA-101, has completed successful manufacturing and quality release testing.
Featured Article
Don’t get left behind: Manufacturing’s urgent need for digital transformation
As digital transformation reshapes industries worldwide, manufacturers in Australia and beyond are finding themselves at the forefront of an evolution. This shift presents opportunities for companies looking to improve efficiency, drive innovation, and boost growth.
